Clinical Experience and Outcomes with Triple-drug Fixed-dose Combination Therapy (Sitagliptin + Dapagliflozin + Metformin Sustained-Release Tablets) in Type 2 Diabetes Mellitus Management: A Real-world Observational Survey of Clinician Perspectives

Background and Aim: Type 2 Diabetes Mellitus (T2DM) is a growing global concern driven by genetic, lifestyle, and environmental factors. Risk factors such as obesity, sedentary behavior, and poor diet worsen its progression, leading to complications. Combination therapy offers superior glycemic control by targeting multiple pathophysiological processes, preserving β-cell function, and reducing complications. This cross-sectional observational survey aims to evaluate the clinical experience, effectiveness, safety, and tolerability of the sitagliptin + dapagliflozin + metformin sustained-release (SR) fixed-dose combination (FDC) in the management of T2DM. Materials and Methods: A total of 450 clinicians, including endocrinologists, diabetologists, and general practitioners, participated in the survey. Descriptive statistics were applied, with categorical variables presented as percentages. Graphical representations were created using Microsoft Excel 2024. Results: Key findings revealed that the majority of clinicians ( n = 367; 82%) perceived the triple-drug FDC to be more effective in achieving glycated hemoglobin targets compared to traditional sequential therapy. Cardiovascular (CV) safety was rated highly by 96% ( n =432) of clinicians. Furthermore, 41% ( n = 184) reported that the therapy was well-tolerated by patients, and 54% ( n = 244) reported that the therapy was well-tolerated with occasional mild side effects. The combination was found to be particularly beneficial for patients with uncontrolled diabetes, CV risk factors, and a high pill burden. Conclusions: These findings demonstrate the positive real-world impact of the triple-drug FDC sitagliptin + dapagliflozin + metformin SR tablets on T2DM management. However, the survey’s observational nature, potential selection bias, and reliance on self-reported data may limit the generalizability of the results.

Authors

Institutions

Publication Details

Journal
Archives of Medicine and Health Sciences
Published
2026-01-01
DOI
https://doi.org/10.4103/amhs.amhs_121_25
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Experience and Outcomes with Triple-drug Fixed-dose Combination Therapy (Sitagliptin + Dapagliflozin + Metformin Sustained-Release Tablets) in Type 2 Diabetes Mellitus Management: A Real-world Observational Survey of Clinician Perspectives

Manoj Suva
Archives of Medicine and Health Sciences
Diabetes Treatment and Management
article

Clinical Experience and Outcomes with Triple-drug Fixed-dose Combination Therapy (Sitagliptin + Dapagliflozin + Metformin Sustained-Release Tablets) in Type 2 Diabetes Mellitus Management: A Real-world Observational Survey of Clinician Perspectives

Manoj Suva
article en

Abstract

Background and Aim: Type 2 Diabetes Mellitus (T2DM) is a growing global concern driven by genetic, lifestyle, and environmental factors. Risk factors such as obesity, sedentary behavior, and poor diet worsen its progression, leading to complications. Combination therapy offers superior glycemic control by targeting multiple pathophysiological processes, preserving β-cell function, and reducing complications. This cross-sectional observational survey aims to evaluate the clinical experience, effectiveness, safety, and tolerability of the sitagliptin + dapagliflozin + metformin sustained-release (SR) fixed-dose combination (FDC) in the management of T2DM. Materials and Methods: A total of 450 clinicians, including endocrinologists, diabetologists, and general practitioners, participated in the survey. Descriptive statistics were applied, with categorical variables presented as percentages. Graphical representations were created using Microsoft Excel 2024. Results: Key findings revealed that the majority of clinicians ( n = 367; 82%) perceived the triple-drug FDC to be more effective in achieving glycated hemoglobin targets compared to traditional sequential therapy. Cardiovascular (CV) safety was rated highly by 96% ( n =432) of clinicians. Furthermore, 41% ( n = 184) reported that the therapy was well-tolerated by patients, and 54% ( n = 244) reported that the therapy was well-tolerated with occasional mild side effects. The combination was found to be particularly beneficial for patients with uncontrolled diabetes, CV risk factors, and a high pill burden. Conclusions: These findings demonstrate the positive real-world impact of the triple-drug FDC sitagliptin + dapagliflozin + metformin SR tablets on T2DM management. However, the survey’s observational nature, potential selection bias, and reliance on self-reported data may limit the generalizability of the results.

Archives of Medicine and Health SciencesVol. 14(1)
TCG Lifesciences (India) (IN)
No poverty
Openalex Percentile: Top 4%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical Experience and Outcomes with Triple-drug Fixed-dose Combination Therapy (Sitagliptin + Dapagliflozin + Metformin Sustained-Release Tablets) in Type 2 Diabetes Mellitus Management: A Real-world Observational Survey of Clinician Perspectives — Manoj Suva · Archives of Medicine and Health Sciences (2026) | TGRS Research Map | TGRS